Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Entero Therapeutics Inc ENTO

Healthcare Biotechnology
Entero Therapeutics, Inc., formerly First Wave BioPharma, Inc., is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Its programs address unmet needs in GI health and include latiglutenase, a Phase III-ready, oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of... see more

Recent & Breaking News (NDAQ:ENTO)

AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production

GlobeNewswire November 10, 2020

AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives

GlobeNewswire October 29, 2020

AzurRx BioPharma Announces Formation of Scientific Advisory Board

GlobeNewswire October 21, 2020

AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis

GlobeNewswire October 14, 2020

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire October 7, 2020

AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference

GlobeNewswire September 15, 2020

LD Micro - 360 Companies Set to Present this Week

Accesswire August 31, 2020

AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4)

GlobeNewswire August 31, 2020

AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire August 17, 2020

AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire August 13, 2020

AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders

GlobeNewswire August 12, 2020

AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire August 11, 2020

LD Micro Announces Preliminary List of Presenters for the LD 500

Accesswire August 5, 2020

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire July 22, 2020

AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis - with First Patient Screened and Three Clinical Trial Sites Activated

GlobeNewswire July 22, 2020

AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange

GlobeNewswire July 20, 2020

AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product

GlobeNewswire May 7, 2020

AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)

GlobeNewswire May 5, 2020

AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

GlobeNewswire April 30, 2020

AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites

GlobeNewswire April 29, 2020